A flawed investment: Neurodiversity conversion therapies

An indisputable shift is underway within the financial world. ESG has become a key investing factor, which has led to a surge of investment in healthcare, especially following the Covid-19 pandemic.

One of the areas that has benefited from this increased attention and subsequently, investment, are behavioural therapy companies. One healthcare M&A firm, recently reporting on the industry, noted an increase in deals in 2021 focusing on behavioural therapy companies, with 57 deals for autism or neurodiversity-focused therapies being completed within the last two years alone. But do these portfolio companies qualify as ESG and more fundamentally, are they moral to begin with, and should the investment world really be investing in them? The idea that mainstream investment firms could ...